Member Info for Saxondale

Nope, other than that Faron are supposed to be having FDA meetings this quarter, also in discussion with DofD regarding Traumakine , and also at Jefferies Conference in London .
They are hoping to get a Bexmab poster out too in November .
Could just be rumblings of some good news from any of those areas .
I've been checking what I can , but apart from a new patent , nothing much else to go on this week .
I even looked the Finnish chat board for hints , but they are as much in the dark as us lol .

Partly I think its because we were just too cheap .
We are all happy at 59% jump , but it was basically a 59% rise from somewhere we shouldn't have been .

Lots of new investors today ( like me ) - some short term , others will read up quickly and see the value potential .
Don't normally jump onboard once the train has left the station , but this one seems to have legs.
Well done holders , nice to see good news and people doing well .

The max number of shares I can get an instant quote on is 8 ( £28 worth @ £2.50)
Despite the SP rising , doesn't appear to be many people willing to sell up yet .
Add another zero and we'll talk .

Nas up 26% at 2.90 euro
£2.35 to buy here at the moment and £2.30 to sell
Good day - news to come surely after this sort of jump ?

Brings back memories of the ' good old days' when we could move £1 in a flash .
When the action starts here , the volume goes nuts .
Fingers crossed we are getting towards that fabled SSV !

Jefferies conference in London at the moment .
Faron attending . Would be nice to think that finally we are starting to get noticed as a potential sleeping Giant with the Bex program .
£2.13 to buy

New patent posted
https://patents.justia.com/patent/20220357348

I've chopped out a few key paragraphs , but it looks like they have an enhanced method for determining the effectiveness and potency of Bex .
Beyond my understanding to be honest , but it looks like they can use this LDL measurement to fine tune Bex efficacy .
And also check it is potent in different stages of manufacture/shelf life .
Also looks like it hints on potential use as a novel treatment for high cholesterol / vascular disease due to what Bex does to the LDLs .

It seems every time they get more data on Bex and Clever-1 , they uncover another important function / use for Bex .
The case for Bex gets stronger and stronger .
Great stuff !

A potency testing is an integral in determining a drug's specific ability or capability to produce a given result.
it has been found that anti-Clever-1 antibodies which specifically bind to certain epitope sequences or at least partly to the certain defined epitope sequences of Clever-1 inhibits and/or blocks modified LDLs, particularly acLDL, uptake efficiently.

The findings of the present invention enable evaluating the biological activity of a therapeutic anti-Clever-1 antibody by determining inhibition and/or blocking uptake of modified low-density lipoprotein, particularly acetylated low-density lipoprotein (acLDL) on Clever-1 presenting cells, and hence the present invention provides a method and an assay for determining a potency of a therapeutic anti-Clever-1 antibody or fragment(s) thereof capable of binding to human Clever-1 and inhibiting its' function.
A method or assay according to the present invention can be used for potency testing of anti-Clever-1 antibodies during product characterization and stability testing.

Further, it is supposed that an anti-Clever-1 antibody binding to the Clever-1 receptor reduces the number of receptors available on the cell surface for modified low-density lipoproteins, such as acLDL, binding and hence preventing macrophage LDL cholesterol uptake and foam cells formation, i.e. the precursor of an atherosclerotic plaque. This has been observed as an increase in free LDL in cell cultures, and an increase in LDL levels of cancer patients treated with an anti-Clever-1 antibody FP-1305. Hence, the findings of the present invention may provide a novel treatment for atherosclerotic cardiovascular disease and thus reduce or even eliminate the development of atherosclerotic plaques caused by macrophages digesting modified LDLs in situation where there is excess LDL. These situations are most commonly referred to as hypercholesterolemia or dyslipidemia.

Nice to see SP coming back towards some reality , but we are still miles off where we should be .
Still , news should be coming soon regarding -
FDA meeting for Matins trial - will set the plan then for how they proceed into P3 trials ( Q4 2022 )
Further Bexmab data , plus perhaps a LBA poster ( mentioned that it may be in Nov )
Traumakine future plans ( been told to expect that - sale / DofD new trial / FDA meeting for approval ? )
Haematokine IND submission ?
US developments ?
Bexlung trial ( in Texas ) planned to start in Dec 2022

Can't get a quote for any amount to buy this morning .
People holding their shares tight .

Interesting bit of info in interview with MLF .
The first patient that showed some efficacy in Bexmab , had been on SOC , but was not responding . With Bex - he began responding again - and showed a reduction of cancer cells in the bone marrow .
Pretty good showing for your first patient !

Her words - super exciting - and looking forward to next dosing and other combination studies .

Update on Matins - currently looking at more frequent dosing . seem to be homing in on Melanoma as favourite - due to such improved life expectancy .
Bexcombo - immune activation so important for PD1 blockers . Trial plans being drawn up.

https://www.youtube.com/watch?v=59V68CY0ikI

No sign of Bexcombo on Clinicaltrials.com yet .
Despite it planning to start in Q1 2023 .
Even Bexlung is listed ( starting Dec 2022) , and has been for months .
At least that is sponsored by Uni of Texas San Antonio

Perhaps they are negotiating with a partner/sponsor for what has always been seen as the biggest potential blockbuster use of Bex .

Like Ques says , funding is the elephant in the room , despite us having enough to see us through Q1 2023 .
These trials are expensive .
Bexmab may throw us an early cash cow , but surely they have enough trials in play now ( with matins FDA meeting being key ) to start putting some deals in place .

Evolving data....
Not only a biomarker for Bex efficacy , but they now see that IFN y levels are key for a PD1/PDL1 therapy .
The case for Bex continues to build.

Clinical data show that 65-80% of cancer patients do not respond to single agent PD-1 blockade and evolving data suggest that IFN-? expression is required for response to PD-1 blockade. Bexmarilimab induces IFN-? upregulation, which is required for immune modulation in the tumor microenvironment, T cell activation and ultimately response to PD-1/PD-L1 inhibition therapy. Bexmarilimab ignites the immune response in tumors without preexisting immune activation, and the BEXCOMBO study thereby offers the opportunity to expand the population of responders and provide meaningful benefit to more patients.

Bexcombo news now .
They sure are throwing the kitchen sink at Bex now , and more evidence being posted next week as to the importance of Clever-1 .
Great to see they are going to up their chances in Bexcombo by patient selection based on all their experience of who will most likely benefit .
Up to 10 sites in US and Europe planned.

BEXCOMBO is a Phase II study that aims to enrol up to 120 patients in a single-arm, multicenter, adaptive design trial. A Simon's 2-Stage design is planned to evaluate 15 patients in Stage 1 and an additional 25 patients in Stage 2 per indication. The study design includes a safety run-in and allows for enrichment of patient populations based on CLEVER-1 expression level, PD-L1 status or biomarkers predictive of response based on emerging non-clinical and clinical data. The study indications include metastatic or unresectable, recurrent HNSCC, locally advanced or metastatic UCC and metastatic NSCLC where first-line PD-1 blockade is approved standard of care. Enrollment is planned to begin in Q1 2023, with up to 10 clinical trial sites across the US and Europe. The primary objective is to evaluate the clinical efficacy of the combination therapy bexmarilimab plus PD-1 blockade based on objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

This firework obviously has the worlds longest fuse

Lets see if that Leukemia Society steps up their involvement after this .
They've been known to invest big amounts .
Bexmab has the potential to give Faron early income stream .
Remember - all of this is still 100% wholly owned at the moment .
Big relief on this news - it means they have a much stronger hand .
It's doing what they said it could do.

Lots of info here that could relate to Matins meeting too -

Initial data from patients dosed with bexmarilimab also show a significant reduction in levels of soluble Clever-1 protein in the blood of treated patients.

Just this comment alone is pretty big .

5 patients treated so far since June - all still alive .

Only being given 1mg/kg so far . Now upping to 3mg .

So great signals even from the lowest dose level .

This has to bode well , as we know how well tolerated Bex is .

This is v good news !

Huge even.

MLF-
"We have also observed an early indicator of clinical benefit in the first patient dosed, alongside the observation of a reduction in levels of immunosuppressive soluble Clever-1 protein in the blood of treated patients."

"The BEXMAB study is off to a great start, and we are eagerly waiting to see the first data from the triplet therapy, where bexmarilimab could become a cornerstone of first-line treatment in newly diagnosed AML patients," said CEO Markku Jalkanen. "We wish to thank our investigators, and especially patients, for the wonderful start of this trial, and their commitment in helping to find new treatments for this grave condition."

Just watched podcast ( with a few drinks too ) . Added a bit today again . Wow this is going to be big .
Have taken a step back from watching SP too much ( bad for health) , and actually enjoying the journey a whole lot more now .
Well done fellas . We are all learning as this progresses .

5 conferences and 2 investor events just popped up on Faron website today .
https://www.faron.com/investors/calendar
FDA meeting this quarter too , along with possible Bexmab data and LBA posting .
Traumakine FDA meeting too ?

https://www.ts.fi/uutiset/5795127
Promising results from Turku-based pharmaceutical company Faron's cancer drug
Dr. Anna Minchom from the Royal Marsden Hospital said in Faron's press release that doctors still have few approved immunotherapeutic treatments. However, very few patients can be treated with effective immunotherapy.

Minchomin says that Faron's bexmarilimab is a very interesting addition to the offering. He sees that in the future, bexmarilimab could work well with other immunotherapies.

https://www.labiotech.eu/trends-news/beyond-biotech-podcast-18-biotechx-cultivated-epfl-faron/?utm_campaign=newsletter-442&utm_medium=email&utm_source=newsletter&mc_cid=e92c9a06bb&mc_eid=1a6900b860